<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976920</url>
  </required_header>
  <id_info>
    <org_study_id>OLM001</org_study_id>
    <nct_id>NCT04976920</nct_id>
  </id_info>
  <brief_title>Metabolomics Non Selection Study - Vitrolife Media</brief_title>
  <official_title>Non-selection Trial Comparing Metabolomics to PGT-A Embryo Selection Using Vitrolife G-TL Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Overture Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Juana Crespo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Overture Life</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, study investigators will collect embryo culture media on day 5 of vitro&#xD;
      fertilization (IVF) culture, prior to vitrification and embryo transfer for testing via&#xD;
      Metabolomic screening. Metabolomics is a new, non-invasive method of embryo selection which&#xD;
      involves testing discarded embryo culture media for analytes secreted by the developing&#xD;
      embryo. These analytes can be used to determine the implantation potential, and ploidy, of&#xD;
      the embryo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg&#xD;
      retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All&#xD;
      fertilized oocytes will be cultured up to blastocyst for five to six days.&#xD;
&#xD;
      Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on&#xD;
      day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab&#xD;
      for metabolomic analysis.&#xD;
&#xD;
      For the embryo transfer, the best morphology blastocyst will be selected for transfer by the&#xD;
      New Hope embryologist.&#xD;
&#xD;
      Approximately 8-11 days after the embryo transfer, the patient will return to the clinic for&#xD;
      a serum pregnancy test. Should the test be negative, they will be closed out of the study.&#xD;
      Should the test be positive, they will continue to be monitored.&#xD;
&#xD;
      The patient will return to the clinic at approximately 8 weeks after embryo transfer for a&#xD;
      serum pregnancy test, and an ultrasound to detect fetal heartbeat. The outcome will be&#xD;
      documented and the patient closed out of the study at this time.&#xD;
&#xD;
      The embryo transfer outcome will be compared to the metabolomics result to determine the NPV&#xD;
      and PPV of metabolomics vs implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative predictive value (NPV) and positive predictive value (PPV) for MEI vs. expected implantation based solely on morphology.</measure>
    <time_frame>Approximately 4-5 months, inclusive of IVF cycle, embryo transfer and monitoring up to eight weeks</time_frame>
    <description>PPV (MEI high potential implanting / Total implanting), NPV (MEI low potential implanting / Total not implanting)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <description>Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days.&#xD;
Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis.&#xD;
For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Overture Metabolomics Embryo Selection</intervention_name>
    <description>Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients recruited from an IVF center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women of any age, 25% of patients &lt;35 years, 25% of patients 35-37, 25% of patients&#xD;
             38-40, and 25% of patients &gt;40 years.&#xD;
&#xD;
          -  Signed Subject Consent Form. No inferior limit on number of eggs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        At the time of initial visit:&#xD;
&#xD;
          -  Require or request PGT of any kind&#xD;
&#xD;
          -  Low ovarian reserve defined as follicle stimulating hormone (FSH) &gt;10 IU/L on day 2-4&#xD;
             of a prior menstrual cycle and anti-mullerian hormone (AMH) &lt;15 pmol/L (or &lt;2 ng/ml)&#xD;
             within prior 12 months of cycle start&#xD;
&#xD;
        At the time of embryo selection:&#xD;
&#xD;
        -Patients without at least one embryo to transfer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Horcajadas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overture Life</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santiago Munne, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overture Life</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Nadal</last_name>
    <phone>323-420-6343</phone>
    <email>alex@overture.life</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Cabello</last_name>
    <email>sara@overture.life</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Juana Crespo</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Teruel Lopez</last_name>
    </contact>
    <investigator>
      <last_name>Juana Crespo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Overture Life</investigator_affiliation>
    <investigator_full_name>Dr. Jose Horcajadas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>genetic screening</keyword>
  <keyword>preimplantation genetic testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be presented at industry conferences, and published in peer reviewed journals.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

